Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KARS1 | Q15046 | 15/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.35 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.34 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776126 | 0.90 | KARS1 (0.39) | KARS1PRKD1PRKD2FGFR4 | |
| SCHEMBL16776171 | 0.88 | KARS1 (0.48) | KARS1DYRK1APRKD1PRKD2GSK3B | |
| SCHEMBL16776163 | 0.84 | FGFR4 (0.40) | KARS1DYRK1APRKD1PRKD2FGFR4 | |
| SCHEMBL16776027 | 0.83 | KARS1 (0.44) | KARS1FGFR4 | |
| SCHEMBL16776063 | 0.83 | MAP4K4 (0.40) | KARS1GSK3B | |
| SCHEMBL16776016 | 0.83 | WNT3A (0.40) | KARS1 | |
| SCHEMBL16776077 | 0.81 | DYRK1A (0.35) | KARS1DYRK1AWNT1GSK3B | |
| SCHEMBL19365800 | 0.80 | KARS1 (0.37) | KARS1DYRK1AWNT1GSK3B | |
| SCHEMBL16776107 | 0.80 | RAB9A (0.37) | DYRK1AGSK3BFGFR4 | |
| SCHEMBL16776129 | 0.80 | FGFR4 (0.42) | KARS1DYRK1AWNT1GSK3BFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | KARS1 1760/4885DYRK1A 2623/4885PRKD1 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.